Estrogen-associated COX-2 pathways explain protection from heart disease in f...( (Philadelphia PA) - Heart disease is l...),Health

(Philadelphia, PA) - Heart disease is less pronounced in women than in men as humans age, but this difference narrows after menopause. Some studies have shown that estrogen slows heart disease in mouse models, but the mechanism is largely unknown. Now scientists from the University of Pennsylvania School of Medicine show for the first time that in female mice protection from hardening of the arteries purported to come from higher levels of estrogen acts predominately through cyclooxygenase (COX)-2.

Garret FitzGerald, MD, Chairman of the Department of Pharmacology, and colleagues found that estrogen binds to a cell receptor that activates COX-2, which in turn ramps up the production of the prostacyclin PGI2. This biochemical provides protective benefits both by inhibiting platelet activation and by reducing oxidative stress in the circulatory system by increasing expression of an antioxidant enzyme. Earlier experiments in mice by the FitzGerald lab and others have shown that platelet activation and oxidative stress can independently hasten hardening of the arteries. The most recent findings appear in the November 18 issue of Science.

This study shows for the first time that prostacyclin can modulate gender differences in atherosclerosis and that estrogen increases prostacyclin in an animal model. In addition, this research also demonstrates that estrogen upregulates COX-2-dependent prostacyclin and that prostacyclin contributes to the atheroprotective effect of estrogen.

Disabling the prostacyclin receptor in female mice whose ovaries have been removed took away the atheroprotective effect of estrogen. By taking away the ovaries, the investigators can pinpoint the direct effects of estrogen. In mice treated this way, estrogen, as expected, slows hardening of the arteries. Taking away the receptor for PGI2 in those animals largely undermines this protection, which was based on measuring the extent of atherosclerosis. Increased platelet acti
'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
18-Nov-2004

Page: 1 2
Related medicine news :

1. COX-2 inhibitors associated with blood pressure elevation
2. COX-2 product offers good and bad news in test tube strokes
3. COX-2 inhibitor increases the risk of heart attack in elderly adults with no history of heart attack
4. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
5. Special JAMA commentary on lessons learned from troubles with COX-2 inhibitors
6. NIH halts use of COX-2 inhibitor in large cancer prevention trial
7. COX-2 inhibitor could be safest anti-inflammatory drug for older people
8. Lupus discovery may pave way to better-designed COX-2 inhibitors
9. Study findings question COX-2 drug cost effectiveness
10. COX-2 inhibitors and the elderly
11. Aspirins target, the COX-2 enzyme, linked to cancer of the uterus